- Home
- IOBT vs MDXH Comparison
IOBT vs MDXH Comparison
Compare IOBT & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- MDXH
- Stock Information
- Founded
- IOBT 2014
- MDXH 2003
- Country
- IOBT Denmark
- MDXH Belgium
- Employees
- IOBT N/A
- MDXH N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- MDXH
- Sector
- IOBT Health Care
- MDXH
- Exchange
- IOBT Nasdaq
- MDXH Nasdaq
- Market Cap
- IOBT 62.6M
- MDXH 73.3M
- IPO Year
- IOBT 2021
- MDXH 2021
- Fundamental
- Price
- IOBT $1.00
- MDXH $1.87
- Analyst Decision
- IOBT Strong Buy
- MDXH Buy
- Analyst Count
- IOBT 3
- MDXH 1
- Target Price
- IOBT $9.33
- MDXH $6.00
- AVG Volume (30 Days)
- IOBT 83.8K
- MDXH 49.3K
- Earning Date
- IOBT 05-20-2025
- MDXH 05-14-2025
- Dividend Yield
- IOBT N/A
- MDXH N/A
- EPS Growth
- IOBT N/A
- MDXH N/A
- EPS
- IOBT N/A
- MDXH N/A
- Revenue
- IOBT N/A
- MDXH $90,049,000.00
- Revenue This Year
- IOBT N/A
- MDXH $23.38
- Revenue Next Year
- IOBT N/A
- MDXH $16.84
- P/E Ratio
- IOBT N/A
- MDXH N/A
- Revenue Growth
- IOBT N/A
- MDXH 28.29
- 52 Week Low
- IOBT $0.66
- MDXH $1.35
- 52 Week High
- IOBT $1.79
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- IOBT 52.54
- MDXH 68.09
- Support Level
- IOBT $0.95
- MDXH $1.67
- Resistance Level
- IOBT $1.20
- MDXH $1.82
- Average True Range (ATR)
- IOBT 0.09
- MDXH 0.10
- MACD
- IOBT 0.01
- MDXH 0.01
- Stochastic Oscillator
- IOBT 43.10
- MDXH 86.14
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.